Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL - PubMed

Review

Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL

M Sattler et al. Cytokine Growth Factor Rev. 1997 Mar.

Abstract

BCR/ABL is a human chimeric oncogene that causes chronic myelogenous leukemia (CML). The BCR/ABL oncogene is generated from the Philadelphia chromosome (Ph) translocation, t(9;22)(q34;q11), and creates a constitutively active tyrosine kinase. There is clonal expansion of hematopoietic stem cells of several different lineages in CML. CML patients in stable phase usually have high white blood counts and immature cells of granulocytic lineages. Stable phase CML evolves to a more aggressive phase typically within 3.5-5 years, where differentiation is blocked and acute leukemia ensues. The transition of CML stable phase to blast phase is reflected in the loss of growth factor requirement of CML cells and correlates with additional cytogenetic alterations. Some biological effects reported in primary CML cells include reduced apoptosis and altered adhesion to fibronectin; however, the cells are dependent on hematopoietic growth factors. On a molecular level, the BCR/ABL translocation is well characterized. However, the actual mechanism of transformation by the BCR/ABL oncogene of hematopoietic cells is largely unknown. Enhancement of the c-ABL tyrosine kinase activity in BCR/ABL appears to be crucial for transformation. This tyrosine kinase activity leads to activation of several signal transduction pathways that are also utilized by hematopoietic growth factors, including steel factor, thrombopoietin, interleukin-3, and granulocyte/macrophage-colony stimulating factor. In several model systems, BCR/ABL has overlapping biological effects with hematopoietic growth factors, and transformation of hematopoietic growth factor-dependent cell lines leads to growth factor independence. In this review, we will describe the molecular and biological abnormalities in CML and several signal transduction mechanisms utilized by BCR/ABL as compared to hematopoietic growth factors.

Similar articles

• Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.

  Warmuth M, Danhauser-Riedl S, Hallek M. Warmuth M, et al. Ann Hematol. 1999 Feb;78(2):49-64. doi: 10.1007/s002770050473. Ann Hematol. 1999. PMID: 10089019 Review.

• The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.

  Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD. Sattler M, et al. Oncogene. 1996 Feb 15;12(4):839-46. Oncogene. 1996. PMID: 8632906

• Molecular mechanisms of transformation by the BCR-ABL oncogene.

  Sattler M, Griffin JD. Sattler M, et al. Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10. doi: 10.1053/shem.2003.50034. Semin Hematol. 2003. PMID: 12783368 Review.

• Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.

  Jain SK, Langdon WY, Varticovski L. Jain SK, et al. Oncogene. 1997 May 8;14(18):2217-28. doi: 10.1038/sj.onc.1201049. Oncogene. 1997. PMID: 9174058

• Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.

  Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Shuai K, et al. Oncogene. 1996 Jul 18;13(2):247-54. Oncogene. 1996. PMID: 8710363

Cited by

• A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.

  Johnson KJ, Griswold IJ, O'Hare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ. Johnson KJ, et al. PLoS One. 2009 Oct 13;4(10):e7439. doi: 10.1371/journal.pone.0007439. PLoS One. 2009. PMID: 19823681 Free PMC article.

• Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors.

  Ikeda D, Chi S, Uchiyama S, Nakamura H, Guo YM, Yamauchi N, Yuda J, Minami Y. Ikeda D, et al. Int J Mol Sci. 2022 May 25;23(11):5950. doi: 10.3390/ijms23115950. Int J Mol Sci. 2022. PMID: 35682627 Free PMC article. Review.

• Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.

  Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. Slupianek A, et al. Mol Cell Biol. 2002 Jun;22(12):4189-201. doi: 10.1128/MCB.22.12.4189-4201.2002. Mol Cell Biol. 2002. PMID: 12024032 Free PMC article.

• Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

  Pene-Dumitrescu T, Smithgall TE. Pene-Dumitrescu T, et al. J Biol Chem. 2010 Jul 9;285(28):21446-57. doi: 10.1074/jbc.M109.090043. Epub 2010 May 7. J Biol Chem. 2010. PMID: 20452982 Free PMC article.

• Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

  Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Jiang X, et al. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12804-9. doi: 10.1073/pnas.96.22.12804. Proc Natl Acad Sci U S A. 1999. PMID: 10536003 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal